CliffBio
small molecule

MODEYSO

DORDAVIPRONE HYDROCHLORIDE

Loss of exclusivityJanuary 2037latest FDA-listed patent expiry
CompanyChimerix →View the full company profile on CliffBio

Drug detail

Brand nameMODEYSO
Active ingredientDORDAVIPRONE HYDROCHLORIDE
StrengthEQ 125MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2025
Marketing statusRX

Listed patents

PatentExpiresType
10172862January 2037use U-4254
12102639January 2037use U-4254
10369154January 2037use U-4254
11976068March 2036product
9265765July 2034product
9629842April 2032use U-4254
RE46290April 2032use U-4254

Regulatory exclusivity

CodeExpires
ODE-547August 2032
NCEAugust 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MODEYSO patent cliff — loss of exclusivity January 2037 | CliffBio